The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Highlights in AML and MDS from EHA 2022
Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, shares some key highlights in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) from the EHA 2022 meeting. Dr Shimony first comments on the excitement around the novel Molecular International Prognostic Scoring System (IPSS-M) in MDS, and further discusses clinical trial updates from the meeting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
